+Vote!
PharmaGazette (Free subscription) | yesterday
In a report published in the online edition of The Lancet Dr. Robert J. Motzer, from Sloan-Kettering Cancer Center in New York reported that treatment with everolimus improved the progression-free survival of patients with advanced kidney cancer who had not responded to other treatments. The study involved 410 patients with kidney cancer that has metastasized to other parts of the body despite treatments...
+Vote!
Reuters (Free subscription) | yesterday
NEW YORK (Reuters Health) - Treatment with everolimus can significantly improve the progression-free survival of patients with advanced kidney cancer that has not responded to other treatments, according to a report in the online issue of The Lancet.
+Vote!
Reuters UK (Free subscription) | yesterday
NEW YORK (Reuters Health) - Treatment with everolimus can significantly improve the progression-free survival of patients with advanced kidney cancer that has not responded to other treatments, according to a report in the online issue of The Lancet.
1Vote!
Red Orbit (Free subscription) | 07/21/2008
A study of patients with kidney cancer has shown that radiofrequency ablation, a minimally invasive, kidney-sparing procedure, can be a successful treatment option for patients whose cancer has not spread beyond the kidney, report researchers at Wake Forest Baptist Medical Center.
1Vote!
Red Orbit (Free subscription) | 07/21/2008
The National Health Service in England has refused to give a patient with advanced kidney cancer a new drug even though the medicine is being provided free.
+Vote!
Philadelphia Inquirer (Free subscription) | 07/17/2008
Lawrence J. "Larry" Sugden, 54, a longtime high school and college football referee and, in his wife's words, a "gentle giant," died July 10 at Delaware County Memorial Hospital after a nearly two-year battle with kidney cancer.
1Vote!
VitaBeat (Free subscription) | 07/17/2008
Anti-rejection drugs given after life-saving organ transplants put them at a higher risk of developing cancer, according to a new study. Researchers at Harvard Medical School implanted human kidney cancer cells into mice and then gave the rodents cyclosporine, an immunosuppressant drug often used after transplants. Mice that received the drug grew tumors at a faster rate than mice left untreated.
1Vote!
Red Orbit (Free subscription) | 07/13/2008
By Vanessa Willis, The Charlotte Observer, N.C. Jul. 13--Texas Roadhouse restaurants in Concord and Pineville will host a fundraiser this week for Adam Tanksley, a 4-year-old Waxhaw boy who has a rare pediatric kidney cancer. Ten percent of sales from 4 to 6 p.m.
+Vote!
VitaBeat (Free subscription) | 07/12/2008
California researchers say they have developed molecule-sized "hypodermics" called nanoparticles that deliver drug agents to stop pancreatic and kidney cancer from spreading in mice but have fewer side effects than traditional chemotherapy. A team from the University of California San Diego (UCSD), say that because the nanoparticles target only the cells causing the tumor, such drugs could make for...
+Vote!
Medical News Today (Free subscription) | 07/09/2008
Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ. But that could change, thanks to a new molecule found by Stanford University School of Medicine researchers that kills kidney cancer cells. Ideally, the researchers said, a drug created from this molecule would help fight the life-threatening disease while leaving patients' kidneys intact.
+Vote!
Curing Death by Curing Aging (Free subscription) | 07/09/2008
Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ.
+Vote!
Red Orbit (Free subscription) | 07/07/2008
Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ. But that could change, thanks to a new molecule found by Stanford University School of Medicine researchers that kills kidney cancer cells.
+Vote!
Medical News Today (Free subscription) | 07/05/2008
A randomized trial that studied the impact of the new vitespen vaccine, administered after surgery for kidney cancer, failed to demonstrate an increase in recurrence-free survival (RFS). More research is needed, according to the study authors, in order to know whether the vaccine can increase RFS if given to patients during the early stages of the disease.
+Vote!
BBC News (Free subscription) | 07/04/2008
A judge asks an NHS panel to review a decision to deny a kidney cancer sufferer a life-enhancing drug.
